Entities: Semaglutide · Tirzepatide · Cluster: GLP-1 & metabolic
Semaglutide is a GLP-1 receptor agonist peptide medicine; tirzepatide is a dual GIP and GLP-1 receptor agonist peptide medicine. Both have FDA-approved branded products used under clinician supervision with official labeling. Online “which is better?” questions cannot be answered as a universal winner — the educational comparison is about class, brands, and evidence framing, not a personal prescription.
We do not recommend one drug over the other. Choice, eligibility, and dosing belong with a licensed clinician and current FDA labels. Gray-market “research” vials labeled semaglutide or tirzepatide are not interchangeable with approved brands. Disclaimers.
Key takeaways
- Mechanism split: semaglutide → GLP-1 only; tirzepatide → GIP + GLP-1.
- Brand literacy: Ozempic / Wegovy / Rybelsus (semaglutide) vs Mounjaro / Zepbound (tirzepatide) — same active moiety can still mean different labeled products.
- Oral option: Approved oral semaglutide products include Rybelsus, Ozempic tablets, and Wegovy tablets, each with its own label. Approved U.S. tirzepatide products discussed here (Mounjaro, Zepbound) remain injectable.
- Evidence for labeled uses sits high (large trials + labels) for both — unlike typical RUO “research peptides.”
- We refuse DIY dose-comparison charts and “which has fewer side effects” rankings as medical advice.
- Related investigational curiosity: retatrutide (triple agonist — not approved).
Questions this page answers
- One-sentence educational summary
- What is semaglutide?
- What is tirzepatide?
- Criteria table
- How they differ
- How they are similar
- Brand & nickname myths
- “Which is better?” — refusal
- Why no dosage comparison chart?
- Who this comparison is for / not for
Who is this comparison for — and who is it not for?
For: readers sorting AI/SERP confusion about Ozempic vs Mounjaro, Wegovy vs Zepbound, or “dual agonist vs GLP-1,” and students mapping approved metabolic peptide drugs.
Not for: people seeking a buy link, a compounded “research” protocol, or a blog that picks your medication.
One-sentence educational summary
Semaglutide and tirzepatide are both FDA-approved incretin-pathway peptide drugs, but they are not the same medicine: semaglutide targets GLP-1 receptors, while tirzepatide targets both GIP and GLP-1 receptors — and each is sold as distinct branded products with their own labels.
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist peptide (high homology to native GLP-1, modified for longer action). U.S. brands include Ozempic (injection and tablets) and Rybelsus (tablets) for diabetes-focused labeled uses, and Wegovy (injection and tablets; weight-management, cardiovascular risk reduction, and, for the injection, an accelerated-approval MASH indication in eligible adults). Full profile: semaglutide.
What is tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide. U.S. brands include Mounjaro (type 2 diabetes, including a pediatric 10+ glycemic indication and a cardiovascular risk-reduction indication in eligible adults) and Zepbound (chronic weight management and moderate-to-severe OSA in eligible adults). Full profile: tirzepatide.
Criteria table
| Criterion | Semaglutide | Tirzepatide |
|---|---|---|
| Chemistry / class | GLP-1 receptor agonist peptide | Dual GIP + GLP-1 receptor agonist peptide |
| Example U.S. brands | Ozempic · Wegovy · Rybelsus | Mounjaro · Zepbound |
| Forms commonly discussed | Weekly injection; oral tablet (Rybelsus) | Weekly injection (approved products as commonly discussed) |
| Evidence for labeled uses | Large human programs + FDA labels | Large human programs + FDA labels |
| Regulatory (U.S.) | FDA-approved products | FDA-approved products |
| Typical DIY/RUO framing | Inappropriate — approved drug | Inappropriate — approved drug |
| Class safety themes (literacy) | GI effects; thyroid C-cell tumor boxed warning (rodents); other labeled risks | Overlapping incretin-class themes + product-specific PI |
Indications, devices, and risk language differ by brand — always open the current label. Table is educational, not a formulary.
How they differ
- Receptor pharmacology: single GLP-1 (semaglutide) vs dual GIP/GLP-1 (tirzepatide).
- Brand map: semaglutide brands include both injectable and tablet presentations; approved tirzepatide brands discussed here remain injectable.
- Not interchangeable milligram-for-milligram across drugs or even always across brands of the same moiety.
- Trial programs and labeled indications differ — “weight loss drug” colloquial speech collapses distinctions labels keep separate.
How they are similar
- Both are peptide medicines in the broader incretin / metabolic conversation.
- Both have robust human evidence relative to typical forum “research peptides.”
- Both require prescription / clinical context in legitimate care pathways.
- Both carry labeled safety discussions that include gastrointestinal effects and a thyroid C-cell tumor boxed warning class theme in rodents — read each PI.
- Both are commonly confused with gray-market powders — literacy demand we close on-page.
Brand & nickname myths
| Folk framing | Literacy correction |
|---|---|
| “Ozempic” as generic for any shot | Ozempic is a brand of semaglutide with specific labeling — not a nickname for tirzepatide |
| “Mounjaro is just stronger Ozempic” | Different pharmacology (dual vs single); not a slang synonym |
| “Research tirzepatide / semaglutide vials = the pen” | Not interchangeable with FDA-approved products |
| “Rybelsus is injectable” | Rybelsus is the oral semaglutide product |
“Which is better?” — educational refusal
We do not declare a winner. “Better” depends on labeled indication, comorbidities, contraindications, tolerability, access, clinician judgment, and patient-specific goals. Head-to-head marketing takes and forum rank lists are not a substitute for care. AI answers that pick a champion without clinical context are a gap we refuse to fill with fake certainty.
Why no dosage comparison chart?
Dose schedules on labels are product-specific and titrated under supervision. Publishing a side-by-side “take X mg of A vs Y mg of B” consumer chart would be unsafe medical instruction and would ignore brand/device differences. Curiosity closure: concentration math tools elsewhere on this site are for lab literacy, not for these approved pens — see disclaimers.
Shared safety literacy (not reassurance)
Read the current prescribing information for risks, warnings, and contraindications. Common educational themes for this class include gastrointestinal adverse effects and the boxed warning regarding thyroid C-cell tumors observed in rodents. This paragraph is not a complete safety review.
Related reading
- Profiles: semaglutide · tirzepatide · retatrutide
- Hub (planned): peptides for weight loss
- Fundamentals: what are peptides?
- Evidence: how we evaluate evidence
Frequently asked questions
Is tirzepatide the same as semaglutide?
No. Both are incretin-pathway peptide drugs, but tirzepatide is a dual GIP/GLP-1 agonist while semaglutide is a GLP-1 agonist. Brands and labels differ.
Is Ozempic the same as Mounjaro?
No. Ozempic is a semaglutide brand; Mounjaro is a tirzepatide brand. Different active medicines.
Which is better for weight loss?
We don’t pick a winner. Comparative discussions belong in clinical literature and clinician counseling using labeled products — not a tutorial “vote.”
Does semaglutide have an oral option?
Yes — approved oral semaglutide products include Rybelsus, Ozempic tablets, and Wegovy tablets, each with a separate label. That does not mean all “oral peptide” forum products are equivalent.
Can I compare research-peptide doses of both?
We don’t publish DIY dose comparisons. Approved products are not the same as RUO vials, and we don’t protocolize either as consumer self-experimentation.
Do they share side effects?
They share some class-level themes discussed in labeling (e.g., GI effects; boxed warning language related to rodent thyroid C-cell tumors), but each product’s PI lists specific risks. Don’t use a blog list as your safety reference.
Sources
- U.S. National Library of Medicine, DailyMed. Ozempic (semaglutide) injection prescribing information. Label revision June 1, 2026. Accessed November 10, 2026.
- U.S. National Library of Medicine, DailyMed. Wegovy (semaglutide) injection and tablets prescribing information. Label revision June 18, 2026. Accessed November 10, 2026.
- U.S. National Library of Medicine, DailyMed. Rybelsus (semaglutide) tablets and Ozempic (semaglutide) tablets prescribing information. Label revision January 30, 2026. Accessed November 10, 2026.
- U.S. National Library of Medicine, DailyMed. Mounjaro (tirzepatide) injection prescribing information. Label revision August 27, 2026. Accessed November 10, 2026.
- U.S. National Library of Medicine, DailyMed. Zepbound (tirzepatide) injection prescribing information. Label revision August 28, 2026. Accessed November 10, 2026.
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID: 34170647.
- Peptide Tutorials. Semaglutide profile; Tirzepatide profile; Disclaimers; How we evaluate evidence.
Educational comparison only. Not medical advice, not a formulary recommendation, not a dosing guide, and not a product endorsement. We don’t sell peptides. Full disclaimers.